Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.54 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | ACLY | P53396 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
| ▸ | SUCNR1 | Q9BXA5 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.44 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9890669 | 0.90 | SUCNR1 (0.47) | PTGDR2FFAR1FFAR4CXCL8CYP2C9 | |
| SCHEMBL9890767 | 0.87 | PTGDR2 (0.50) | PTGDR2FFAR1FFAR4ACLYHPGD | |
| SCHEMBL3738386 | 0.86 | FFAR1 (0.54) | PTGDR2FFAR1FFAR4PTGS1CXCL8 | |
| SCHEMBL9890670 | 0.85 | ACLY (0.50) | PTGDR2CHRM1ACLYKEAP1NFE2L2 | |
| SCHEMBL5440013 | 0.83 | FFAR4 (0.66) | PTGDR2FFAR1FFAR4ACLY | |
| SCHEMBL2393525 | 0.83 | PTGDR2 (0.47) | PTGDR2FFAR1FFAR4CHRM1KDM4E | |
| SCHEMBL21507851 | 0.82 | PTGDR2 (0.50) | PTGDR2FFAR1FFAR4ACLYKDM4E | |
| SCHEMBL9890668 | 0.81 | LMNA (0.51) | PTGDR2CXCL8CYP2C9CHRM1KEAP1 | |
| SCHEMBL3540535 | 0.81 | SUCNR1 (0.56) | PTGDR2FFAR1FFAR4CXCL8CYP2C9 | |
| SCHEMBL15876140 | 0.81 | CAMK2A (0.55) | PTGS1CYP2C9HPGDAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249686-A1 | Modulators of Crth-2 Receptor Activity for the Treatment of Prostaglandin D2 Mediated Diseases | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | claimed |
| EP-1799658-A2 | MODULATORS OF CRTH2 REZEPTOR ACTIVITY FOR THE TREATMENT OF PROSTAGLANDIN D2 MEDIATED DISEASES | AstraZeneca AB (SE) | 2007-06-27 | — | — | EP | claimed |
| WO-2006037982-A2 | MODULATORS OF CRTH2 RECEPTOR ACTIVITY FOR THE TREATMENT OF PROSTAGLANDIN D2 MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2006-04-13 | — | — | WO | claimed |
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
| EP-2374790-A1 | BIPHENYLACETAMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2011-10-12 | — | — | EP | disclosed |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-15 | — | — | US | disclosed |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-15 | — | — | US | disclosed |
| US-20070249686-A1 | Modulators of Crth-2 Receptor Activity for the Treatment of Prostaglandin D2 Mediated Diseases | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249686-A1 | Modulators of Crth-2 Receptor Activity for the Treatment of Prostaglandin D2 Mediated Diseases | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249686-A1 | Modulators of Crth-2 Receptor Activity for the Treatment of Prostaglandin D2 Mediated Diseases | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| EP-1799658-A2 | MODULATORS OF CRTH2 REZEPTOR ACTIVITY FOR THE TREATMENT OF PROSTAGLANDIN D2 MEDIATED DISEASES | AstraZeneca AB (SE) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006037982-A2 | MODULATORS OF CRTH2 RECEPTOR ACTIVITY FOR THE TREATMENT OF PROSTAGLANDIN D2 MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | HRH3, KCNH3, BRPF3 | PTGDR2 1062/4885FFAR1 223/4885FFAR4 621/4885 |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | HRH3, KCNH3, BRPF3 | PTGDR2 1062/4885FFAR1 223/4885FFAR4 621/4885 |
| US-20070249686-A1 | Modulators of Crth-2 Receptor Activity for the Treatment of Prostaglandin D2 Mediated Diseases | PTGDR2, PTGDR, PTGER2 | PTGDR2 1/4885FFAR1 164/4885FFAR4 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.